Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, Differentiation
/ metabolism
B7-H1 Antigen
/ metabolism
Bone Neoplasms
/ drug therapy
Denosumab
/ administration & dosage
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Giant Cell Tumor of Bone
/ drug therapy
Humans
Indoleamine-Pyrrole 2,3,-Dioxygenase
/ metabolism
Male
Middle Aged
Receptors, Immunologic
/ metabolism
Retrospective Studies
Survival Analysis
Treatment Outcome
Tumor Microenvironment
/ drug effects
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 07 2021
20 07 2021
Historique:
received:
07
12
2020
accepted:
05
07
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Giant cell tumor of bone (GCTB) is an intermediate malignant bone tumor that is locally aggressive and rarely metastasizes. Denosumab, which is a receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, can be used to treat GCTB. We focused on potential immunotherapy for GCTB and investigated the tumor microenvironment of GCTB. Programmed death-ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO1) expression and signal-regulatory protein alpha (SIRPα), forkhead box P3 (FOXP3), and cluster of differentiation 8 (CD8) infiltration were assessed by immunohistochemical studies of 137 tumor tissues from 96 patients. Of the naive primary specimens, 28% exhibited PD-L1 expression and 39% exhibited IDO1 expression. There was significantly more SIRPα
Identifiants
pubmed: 34285260
doi: 10.1038/s41598-021-94022-w
pii: 10.1038/s41598-021-94022-w
pmc: PMC8292371
doi:
Substances chimiques
Antigens, Differentiation
0
B7-H1 Antigen
0
CD274 protein, human
0
IDO1 protein, human
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Receptors, Immunologic
0
SIRPA protein, human
0
Denosumab
4EQZ6YO2HI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14821Informations de copyright
© 2021. The Author(s).
Références
Crit Rev Oncol Hematol. 2019 Jan;133:85-91
pubmed: 30661662
Oncoimmunology. 2018 Sep 5;7(12):e1480301
pubmed: 30524886
Mod Pathol. 2019 Apr;32(4):511-523
pubmed: 30367104
Signal Transduct Target Ther. 2020 Mar 6;5(1):16
pubmed: 32296041
Trials. 2019 Dec 19;20(1):753
pubmed: 31856909
Sarcoma. 2010;2010:
pubmed: 20706639
Am J Surg Pathol. 2017 Aug;41(8):1059-1068
pubmed: 28505000
J Pathol Clin Res. 2015 Mar 16;1(2):113-23
pubmed: 27499898
J Clin Oncol. 2019 Apr 20;37(12):946-953
pubmed: 30811285
J Immunother. 2015 Apr;38(3):96-106
pubmed: 25751499
Ann Oncol. 2015 Oct;26(10):2149-54
pubmed: 26205395
J Cancer Res Clin Oncol. 2008 Sep;134(9):969-78
pubmed: 18322700
Pathology. 2017 Aug;49(5):506-513
pubmed: 28688724
Cancer Immunol Immunother. 2017 Jan;66(1):119-128
pubmed: 27853827
JCI Insight. 2017 Jan 12;2(1):e89140
pubmed: 28097229
Hum Pathol. 2018 Mar;73:41-50
pubmed: 29241742
J Thorac Oncol. 2018 Jun;13(6):779-791
pubmed: 29526824
Lancet Oncol. 2019 Dec;20(12):1627-1628
pubmed: 31704135
Histopathology. 2018 May;72(6):914-922
pubmed: 29206281
J Bone Joint Surg Am. 2018 Mar 21;100(6):496-504
pubmed: 29557866
Cancers (Basel). 2020 Apr 03;12(4):
pubmed: 32260165
Clin Cancer Res. 2017 Jan 15;23(2):370-378
pubmed: 27440266
J Clin Oncol. 2016 Apr 20;34(12):e104-6
pubmed: 25311221
Acta Orthop. 2008 Feb;79(1):86-93
pubmed: 18283578
J Cancer Res Clin Oncol. 2020 Oct;146(10):2639-2650
pubmed: 32405745
J Cancer. 2016 Apr 10;7(7):784-93
pubmed: 27162536
Ann Surg Oncol. 2020 Jun;27(6):2102-2109
pubmed: 31773516
Hum Pathol. 2017 May;63:89-97
pubmed: 28235628
PLoS One. 2015 Sep 21;10(9):e0137345
pubmed: 26390038
Oncotarget. 2017 May 2;8(18):30276-30287
pubmed: 28415820
BMC Musculoskelet Disord. 2020 Apr 20;21(1):256
pubmed: 32312263
Am J Surg Pathol. 2016 Jan;40(1):72-80
pubmed: 26414220
Expert Opin Ther Targets. 2020 Oct;24(10):945-951
pubmed: 32799682
Sci Rep. 2016 Jul 26;6:30093
pubmed: 27456063
Eur J Cancer. 2018 Sep;101:20-29
pubmed: 30014971
Lung Cancer. 2019 Feb;128:26-32
pubmed: 30642449
Endocr Pathol. 2018 Mar;29(1):59-67
pubmed: 29372535
Cancer Immunol Immunother. 2020 Sep;69(9):1905-1916
pubmed: 32377818
Oncoimmunology. 2020 Apr 12;9(1):1747340
pubmed: 32313727
Med Mol Morphol. 2020 Mar;53(1):1-6
pubmed: 31748824
Lancet Oncol. 2019 Dec;20(12):1719-1729
pubmed: 31704134
Cancer Sci. 2020 Jul;111(7):2608-2619
pubmed: 32342603
World J Surg Oncol. 2018 Aug 8;16(1):160
pubmed: 30089488
Am J Surg Pathol. 2015 Nov;39(11):1576-83
pubmed: 26457357
Hum Pathol. 2020 Jul;101:31-39
pubmed: 32360490
Clin Cancer Res. 2017 Oct 1;23(19):5789-5801
pubmed: 28634284
Hematol Oncol. 2020 Dec;38(5):680-688
pubmed: 32569413
J Immunother Cancer. 2015 May 19;3:19
pubmed: 25992290
J Cancer Res Clin Oncol. 2020 Oct;146(10):2607-2620
pubmed: 32388585
Nat Genet. 2013 Dec;45(12):1479-82
pubmed: 24162739